Immune booster after CAR-T shows promise in early lymphoma trial

NCT ID NCT05075603

First seen Jun 25, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This early-phase study tested an experimental drug called NT-I7 (efineptakin alfa) in 17 people with relapsed or refractory large B-cell lymphoma who had already received CAR-T cell therapy. The goal was to see if giving NT-I7 after CAR-T is safe and tolerable, and to look for early signs that it might help fight the cancer. The trial focused on finding the right dose and checking for side effects, not yet on proving the treatment works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Efineptakin alfa (NT-I7)
What this could lead to
If it works, this could point toward a way to boost the immune system after CAR-T therapy, potentially improving outcomes for people with hard-to-treat lymphoma.
What could go wrong
This is a very early, small phase 1 trial with only 17 participants, so results may not apply broadly. The main goal is safety, not yet proof of effectiveness, and there is a risk of side effects from the drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DLBCL ARISING FROM FOLLICULAR LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • City of Hope

    Duarte, California, 91010, United States

  • Duke Cancer Institute

    Durham, North Carolina, 27710, United States

  • Washington University in St. Louis

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.